PT19 Analysis of the Access to Medicines for Rare Diseases in Countries from the Balkan Peninsula: A Comparative Analysis
To analyze and compare the access of patients with rare diseases (RDs) to pharmacotherapy by monitoring the legislative procedures and the number of reimbursed orphan medicinal products (OMPs) in Bulgaria, Romania and Greece. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: I. Haygarova, A. Turcu-Stiolica, M.S. Subtirelu, N. Karalazou, I. Paliu, N. Ganov, M. Pesheva, A. Savova, G. Petrova, M. Manova, B. Ivanova, M. Kamusheva Source Type: research
HPR93 Impact of Generic Competition on Prices, Public Spending and Utilization of Antiepileptic Medicines in Bulgaria
To analyze the impact of generic and therapeutic competition on lowest price per DDD (defined daily dose), public spending and utilization of antiepileptic medicines in Bulgaria. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: Z. Mitkova, M. Manova, A. Savova, G. Petrova Source Type: research
HPR1 Bulgaria National Stroke Program: Prevention Strategies
The objective is to assess the effectiveness and potential impact of these strategies in the context of stroke prevention in Bulgaria. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: A. Dacheva, M. Andreyan Georgiev, Y. Vutova, G. Slavchev, S. Djambazov Tags: Health Policy & Regulatory Source Type: research
EPH247 Survival and Risk of Death Analysis of Patients with Myelofibrosis Treated with Ruxolitinib
The aim of this study is to analyze the risk of death and survival of patients with MF treated with ruxolitinib in comparison with the group on standard therapy before ruxolitinib inclusion in the national reimbursement system of Bulgaria. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: V. Stoeva, G. Mihaylov, K. Tachkov, G. Petrova Source Type: research
EPH202 Current Policy, Clinical and Economic Environment of Eye Care and Vision Health in Bulgaria
There is a global call for action for addressing eye health as a public health problem in the World report on vision, prepared by WHO and The United Nations General Assembly resolution on vision. The strategic pillars are the inclusion of eye care in national health plans to achievement of "vision for everyone ” by 2030. The aim of the study is to assess the clinical, economic environment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), and access to therapy. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: L. Ivanova, Z. Mitkova, M. Dimitrova Source Type: research
EPH170 Epidemiology of Stroke in Bulgaria
This abstract aims to present epidemiological data on stroke in Bulgaria, focusing on mortality rates and the impact of ischemic stroke on the population, particularly among the elderly. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: Y. Vutova, A. Dacheva, G. Slavchev, S. Djambazov Source Type: research
EE526 Health Benefits and Cost-Effectiveness Analysis of Early Cervical Cancer Diagnosis in Bulgaria
Cervical cancer (CC) is the second most common cancer among women aged between 15 and 44 in Europe. Annually, nearly 325.3 million women over the age of 15 are at risk of developing CC. Each year approximately 61 072 women are diagnosed with cervical cancer and 25 829 die from the disease. The primary objective of this study was to evaluate the health benefits of early CC diagnosis in Bulgaria. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: G. Slavchev, A. Dacheva, Y. Vutova, S. Djambazov Source Type: research
EE455 Cost Saving Potential of Rapid Microbiological Methods: Case Form Bulgaria
Diagnostic processes performed in clinical microbiology laboratories are evaluated in terms of diagnostic efficacy and cost-effectiveness. Rapid microbiological diagnostic tests are one area of such research, because of their potential to shorten the diagnostic process. The aim of this study is to examine the potential economic benefits of using rapid technologies – fluorescence in situ hybridization (FISH), multiplex polymerase chain reaction (mPCR), and mass spectrometry (MALDI-TOF MS) – for microbiological identification in patients with bloodstream infections (BSI) compared with standard microbiological methods. (S...
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Raycheva, G. Lengerova, M.M. Petrov, M. Murdjeva Source Type: research
EE381 Health Benefits and Cost-Effectiveness Analysis of Early Breast Cancer Diagnosis in Bulgaria
Breast cancer (BC) is one of the leading causes of death among women. Worldwide, BC is responsible for 15% of deaths caused by the disease. According to the World Agency for Research on Cancer (IARC), 1.67 million women worldwide were diagnosed with breast cancer in 2012, with 522,000 dying because of the disease. The primary objective of this study was to evaluate the health benefits of early Breast cancer diagnosis in Bulgaria. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: G. Slavchev, A. Dacheva, Y. Vutova, S. Djambazov Source Type: research
EE377 Budget Impact Analysis of Implementing a Breast Cancer Screening Program in Bulgaria
Breast cancer (BC) accounts for 26.8% of all cancers among Bulgarian women according to the Bulgarian National Cancer Registry, 2017. In 2015, 4037 new cases were registered. The actual incidence rate was 108.1 per 100 000, the actual mortality rate - 35.6 per 100 000. The five-year relative survival rate of BC in Bulgaria is 72.8%. The primary objective of this study was to evaluate the budget impact (BI) of implementing a BC screening program in Bulgaria. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: A. Dacheva, G. Slavchev, Y. Vutova, M. Emilia Krapcheva, S. Djambazov Source Type: research
EE324 Clinical and Economic Evaluation of the Potential Implementation of P4P for Type 2 Diabetes in Bulgaria
The aim of this analysis is to assess the cost-effectiveness of implementing a "pay-for-performance ” program to improve the control of type 2 diabetes, as measured by achieving adequate glycemic control through pharmacotherapy. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: G. Slavchev, A. Dacheva, E. Mekov, S. Djambazov, Y. Vutova Source Type: research
EE291 Budget Impact Analysis of Mrna-1273 (Spikevax) in Patients with COVID-19 in Bulgaria
Vaccination is the safest and most effective means of preventing COVID-19 and limiting the spread of the causative virus (SARS-CoV-2). Currently, more than 100 SARS-CoV-2 vaccines are in clinical trials and 24 are approved for use. Following the introduction and mass administration of vaccines approved in the European Union, there has been a strong reduction in the number of severe COVID-19 variants and deaths worldwide. The primary objective of this study was to evaluate the budget impact (BI) of the pharmacoeconomic performance of COVID-19 vaccine prophylaxis medicines in Bulgaria. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: A. Dacheva, M. Boyan Likomanov, G. Slavchev, Y. Vutova, S. Djambazov Source Type: research
EE228 Cost to Society and Financial Toxicity Related to Personalized Oncology Treatment in Bulgaria
Societal costs and financial toxicity could be impacted by the adoption of regulation and value-based guidelines for shared-decision making (SDM) in clinical practice. The aim of the current study is to assess the possibilities for SDM and the cost to society of cancer therapy in Bulgaria. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Dimitrova, M. Petrov, Z. Mitkova Source Type: research
